Key Points
- Illumina director Keith Meister sold 104,393 shares on May 14 at an average price of $145.34, totaling about $15.17 million. After the sale, he still held 3.5 million shares, reducing his ownership by 2.9%.
- Illumina shares were down 1.2% and opened at $143.24, near the stock’s 12-month high of $155.53. The company’s market cap was about $21.67 billion.
- Illumina reported better-than-expected quarterly results, with EPS of $1.15 versus the $1.05 consensus and revenue of $1.09 billion versus $1.07 billion expected. The company also reiterated FY 2026 guidance of 5.15–5.30 EPS, while analysts currently average a “Hold” rating with a $137.75 target price.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 104,393 shares of the firm's stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the sale, the director owned 3,500,048 shares of the company's stock, valued at $508,696,976.32. This trade represents a 2.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Illumina Trading Down 1.2%
Shares of ILMN stock opened at $143.24 on Friday. The firm has a 50 day moving average price of $128.31 and a two-hundred day moving average price of $129.43. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $21.67 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. Illumina, Inc. has a 12-month low of $78.55 and a 12-month high of $155.53.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Elyxium Wealth LLC bought a new position in shares of Illumina during the fourth quarter worth approximately $25,000. Creative Capital Management Investments LLC increased its holdings in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock worth $26,000 after purchasing an additional 120 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Illumina during the fourth quarter worth approximately $26,000. TD Waterhouse Canada Inc. bought a new position in shares of Illumina during the fourth quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Illumina during the fourth quarter worth approximately $26,000. 89.42% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. UBS Group restated a "neutral" rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Stifel Nicolaus raised their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a "buy" rating in a research report on Tuesday, January 20th. Weiss Ratings downgraded shares of Illumina from a "hold (c)" rating to a "hold (c-)" rating in a research report on Wednesday, April 29th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research report on Friday, February 6th. Finally, Piper Sandler lowered their target price on shares of Illumina from $195.00 to $170.00 and set an "overweight" rating on the stock in a report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Illumina has an average rating of "Hold" and an average target price of $137.75.
Get Our Latest Stock Analysis on ILMN
About Illumina
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
